<DOC>
	<DOCNO>NCT02417935</DOCNO>
	<brief_summary>The main purpose study evaluate effectiveness safety study drug know duloxetine participant diabetic peripheral neuropathic pain .</brief_summary>
	<brief_title>A Study Duloxetine ( LY248686 ) Participants With Diabetic Peripheral Neuropathic Pain ( DPNP )</brief_title>
	<detailed_description />
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Diabetic Neuropathies</mesh_term>
	<mesh_term>Duloxetine Hydrochloride</mesh_term>
	<mesh_term>Pregabalin</mesh_term>
	<criteria>Participants present pain due bilateral , peripheral neuropathy Participants hemoglobin A1c ( HbA1c ) ≤9.4 % ( National Glycohemoglobin Standardization Program [ NGSP ] ) screen Participants HbA1c measure 42 70 day prior screen , range variation value measure , thereafter , within ±1.0 % value measure screen Participants score least 4 mean 24hour average pain score measure use 11point NRS daily diary ( calculate record 7 day immediately prior randomization ) Participants make complete daily diary entry 80 % time screen randomization Participants undergone renal transplant , currently undergo renal dialysis Participants uncontrolled narrowangle glaucoma , history uncontrolled seizure , uncontrolled poorly control hypertension Participants whose glycemic control poor within 70 day immediately prior screening ( example , ketoacidosis require hospitalization , hypoglycemia may cause consciousness disorder ) Pregnant lactate female participant , male participant plan partner become pregnant timeframe study Participants hypersensitivity multiple medication Participants answer `` yes '' either question 4 ( active suicidal ideation intent act , without specific plan ) question 5 ( active suicidal ideation specific plan intent ) `` suicidal ideation '' portion ColumbiaSuicide Severity Rating Scale ( CSSRS ) answer `` yes '' suiciderelated behavior ( actual attempt , interrupt attempt , abort attempt , preparatory act behavior ) `` suicidal behavior '' portion CSSRS ; ideation behavior occur within past month Participants past history psychiatric disease , depression , anxiety disorder , eat disorder , etc. , require drug therapy past 1 year , currently complication diseases history manic psychosis bipolar disorder Participants major depressive disorder determine use depression module MiniInternational Neuropsychiatric Interview ( MINI ) Participants complication disease consider affect assessment diabetic peripheral neuropathic pain . For example , nerve disease pain diabetic peripheral neuropathic pain ( cervical spondylosis , carpal tunnel syndrome , spinal canal stenosis , postherpetic pain ) , pain disease nerve disease ( collagen disease , gout , chronic obstructive arteriosclerosis , arthritis ) , pain site evaluation ( skin diseases traumatic injury ) exclude Participants neuropathic pain suspect cause alcohol Participants treat monoamine oxidase ( MAO ) inhibitor ( ) within 14 day immediately prior randomization . Participants visit investigator site 14 day prior randomization , treat MAO inhibitor ( ) , thereafter , exclude Participants alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) level ≥100 units/liter screen Participants total bilirubin level ≥1.5 milligrams/deciliter ( mg/dL ) screen Participants creatinine clearance ( CrCL ) , calculate CockroftGault , &lt; 1.0 milliliters/second ( mL/s ) ( &lt; 60 mL/minute ) screen Participants white blood cell ( WBC ) value &lt; 2500/cubic millimeter ( mm3 ) , neutrophils &lt; 1500/mm3 , platelet &lt; 100×103/mm3 hematology test screen Participants introduce treatment diabetes , change dose regimen treatment diabetes ( exclude insulin treatment ) , resumption insulin treatment screen Participants treat prohibited concomitant drug ( ) , undergone prohibit concomitant treatment ( ) screen Participants take restricted concomitant drug 27 day immediately screen , continue use restrict concomitant drug prior screen Participants take acetaminophen 4 day 7 day immediately prior randomization</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>